Bio adhesive Ophthalmic Treatments Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Bioadhesive Eye Drops, Bioadhesive Gels, Bioadhesive Inserts / Films, Bioadhesive Contact Lenses, Others), By Application (Dry Eye Syndrome, Glaucoma, Conjunctivitis, Corneal Injuries, Post-Surgical Care, Others), By End User (Hospitals & Clinics, Eye Care Centers, Ambulatory Surgery Centers, Home Care, Others) and Region Forecast 2020-2031

Bio adhesive Ophthalmic Treatments Market size was valued at US$ 180.2 million in 2024 and is projected to reach US$ 280.0 million by 2031 at a CAGR of 6.5% form 2025-2031. Moreover, the U.S. Bio adhesive Ophthalmic Treatments Market is projected to grow 6.4%over the forecast period.

The market refers to the segment of ophthalmic therapeutics that utilize Bio adhesive materials to enhance drug delivery and retention time on the ocular surface. These treatments leverage Bio adhesive polymers that adhere to the eye’s mucosal tissues, improving the efficacy and bioavailability of medications used for various ocular disorders such as dry eye, conjunctivitis, glaucoma, and corneal injuries. The Bioadhesive approach addresses the limitations of conventional eye drops by ensuring sustained drug release, reduced dosing frequency, and improved patient compliance.

The market is experiencing steady growth, driven by the increasing prevalence of eye disorders, advancements in ocular drug delivery systems, and the rising demand for non-invasive, patient-friendly therapies. Innovations in polymer science and nanotechnology are enabling the development of next-generation bioadhesive formulations with enhanced biocompatibility and prolonged therapeutic action. Additionally, the growing geriatric population and increased screen exposure leading to ocular surface diseases are further supporting market expansion. Pharmaceutical companies are focusing on developing bioadhesive-based ophthalmic gels, inserts, and films that offer targeted and sustained treatment, positioning this market as a promising area within ophthalmic drug development.

Key Developments

• In August 2025, the U.S. Food and Drug Administration (FDA) approved aceclidine 1.44% ophthalmic solution (Vizz) for the topical treatment of presbyopia. This once-daily eye drop induces pupil constriction, enhancing near vision without significantly affecting distance vision. The approval marks a significant advancement in non-invasive treatments for presbyopia, expanding the scope of bioadhesive ophthalmic therapies.

Bio adhesive Ophthalmic Treatments Market  Segmentation

Based on the product type

• Bioadhesive Eye Drops
• Bioadhesive Gels
• Bioadhesive Inserts / Films
• Bioadhesive Contact Lenses
• Others

The primary driver anticipated to lead growth in the Bioadhesive Ophthalmic Treatments Market is the rising prevalence of dry eye syndrome. Increasing screen time, environmental pollution, and aging populations are significantly contributing to the surge in cases globally. Patients with dry eye often experience discomfort and require frequent administration of conventional eye drops, which face limitations in drug retention and efficacy. Bioadhesive eye drops, gels, and inserts address this challenge by adhering to the ocular surface, ensuring sustained drug release and improved therapeutic outcomes. This increased effectiveness and convenience are driving widespread adoption, positioning dry eye management as the leading market growth factor.

Based on the application

• Dry Eye Syndrome
• Glaucoma
• Conjunctivitis
• Corneal Injuries
• Post-Surgical Care
• Others

Among the applications, the rising incidence of dry eye syndrome is anticipated to be the foremost driver of the Bioadhesive Ophthalmic Treatments Market. Modern lifestyle factors, including prolonged screen exposure, environmental pollution, and aging populations, have significantly increased the prevalence of this condition. Patients often require frequent eye drop administration, which conventional formulations fail to retain effectively on the ocular surface. Bioadhesive ophthalmic treatments, such as gels and inserts, provide sustained drug release and enhanced ocular retention, improving patient compliance and therapeutic outcomes. This growing demand for effective dry eye management is expected to lead market growth in the coming years.

Based on the end user

• Hospitals & Clinics
• Eye Care Centers
• Ambulatory Surgery Centers
• Home Care
• Others

Among end users, hospitals and clinics are anticipated to be the leading driver of growth in the Bioadhesive Ophthalmic Treatments Market. These healthcare settings serve a large number of patients with chronic and acute ocular conditions, including dry eye syndrome, glaucoma, and post-surgical care. Hospitals and clinics prefer bioadhesive formulations due to their sustained drug release, improved efficacy, and ability to reduce dosing frequency, which enhances patient compliance. Additionally, ophthalmologists in these settings are increasingly recommending bioadhesive eye drops, gels, and inserts for better treatment outcomes. The high patient throughput and professional guidance make hospitals and clinics a primary factor driving market expansion.